<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi> therapy has been used to treat patients with <z:hpo ids='HP_0003765'>psoriasis</z:hpo> for more than 20 years </plain></SENT>
<SENT sid="1" pm="."><plain>This regimen has also been used to treat <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp>, and <z:chebi fb="0" ids="50858">corticosteroid</z:chebi>-dependent <z:hpo ids='HP_0002099'>asthma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We report two patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease with cutaneous neutrophilic vascular reactions and three with <z:e sem="disease" ids="C0343190" disease_type="Disease or Syndrome" abbrv="">cutaneous polyarteritis nodosa</z:e> who responded dramatically to low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi> therapy </plain></SENT>
</text></document>